[Pharm-policy] C. A. Heimbold, Jr. pay as CEO of BMS
James Love
love@cptech.org
Tue, 18 Apr 2000 18:17:28 -0400
Here are a few notes from the Bristol-Myers Squibb 14A filing with the SEC.
http://www.sec.gov/Archives/edgar/data/14272/0000950117-00-000657-index.html
Charles A. Heimbold, Jr:
Total Shares of BMS stock owned: 5,207,511
(Value of Shares of BMS stock owned @ $65 a share: $338,488,215)
Shares Aquirable in 60 days: 4,193,550
AGGREGATED OPTION/SAR EXERCISES IN LAST FISCAL YEAR
AND FISCAL YEAR-END OPTION/SAR VALUES(1)
SHARES
ACQUIRED ANNUALIZED
ON VALUE VALUE
EXERCISE REALIZED REALIZED(2)
NAME # $ $
---- -------- ----------- -----------
C. A. Heimbold, Jr....... 776,400 $38,287,872 $8,209,489
K.E. Weg................. 0 $ 0 $ 0
M.F. Mee................. 75,000 $ 3,570,626 $1,011,109
D.J. Hayden, Jr.......... 36,000 $ 1,587,623 $ 215,430
P.S. Ringrose, Ph.D...... 0 $ 0 $ 0
J.L. McGoldrick.......... 60,000 $ 2,871,558 $ 580,109
NUMBER OF SECURITIES VALUE OF UNEXERCISED
UNDERLYING UNEXERCISED 'IN THE MONEY'(3)
OPTIONS/SARS AT OPTIONS/SARS AT
FISCAL YEAR-END FISCAL YEAR-END
# $
--------------------------- ----------------------------
NAME EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
---- ----------- ------------- ----------- -------------
C. A. Heimbold, Jr....... 3,905,000 800,000(4) $156,918,883 $2,771,860(4)
K.E. Weg................. 1,472,934 266,666(4) $ 61,881,137 $ 923,944(4)
M.F. Mee................. 140,000 370,000(4) $ 4,591,558 $6,990,302(4)
D.J. Hayden, Jr.......... 219,760 313,000(4) $ 9,310,427 $3,935,399(4)
P.S. Ringrose, Ph.D...... 145,000 345,000(4) $ 5,011,561 $6,120,305(4)
J.L. McGoldrick.......... 410,000 370,000(4) $ 17,389,366 $6,990,302(4)
ANNUAL COMPENSATION
-----------------------------------
OTHER
ANNUAL
COMPEN-
NAME/TITLE SALARY BONUS SATION(1)
YEAR $ $ $
--------------------- ---------- ---------- ---------
C.A. Heimbold, Jr.
Chairman and Chief
Executive Officer
1999.............. $1,337,500 $2,551,602 --
1998.............. $1,250,000 $1,944,375 --
1997.............. $1,221,000 $1,581,635 --
LONG TERM COMPENSATION
------------------------------------------
AWARDS PAYOUTS
----------------------------- ----------
ALL
RESTRICTED SECURITIES LONG TERM OTHER
STOCK UNDERLYING INCENTIVE COMPEN-
NAME/TITLE AWARDS(2) OPTIONS/SARS(3) PAYOUTS SATION(4)
YEAR $ # $ $
--------------------- ---------- --------------- ---------- ---------
C.A. Heimbold, Jr.
Chairman and Chief
Executive Officer
1999.............. 0 600,000(5) $1,800,000(7) $60,142
1998.............. $21,584,375 600,000(5) $1,129,000(8) $58,240
1997.............. 0 1,200,000(6) $1,121,900(9) $54,935
(footnotes from previous page)
(1) The only type of Other Annual Compensation for each of the named officers
was in the form of perquisites and was less than the level required for
reporting.
(2) Mr. Heimbold, Mr. Weg, Mr. Hayden and Dr. Ringrose were the only named
executives to receive awards in the fiscal years listed. Mr. Heimbold's
awards were granted pursuant to agreements in which Mr. Heimbold agreed to
remain with the Company through December 31, 2001 or earlier if the Board
appoints his successor. Mr. McGoldrick has an outstanding award that was
granted when he joined the Company. Regular dividends are paid on these
shares. The number and market value of shares of restricted stock held by
each of these executives at December 31, 1999 (based upon the closing
market value stock price of $64.1875) were: Mr. Heimbold, 400,000 and
$25,675,000; Mr. Weg, 80,000 and $5,135,000; Mr. Hayden, 100,000 and
$6,418,750; Dr. Ringrose, 140,000 and $8,986,250 and Mr. McGoldrick, 50,000
and $3,209,375.
(3) The number of securities underlying options/SARs has been adjusted to
reflect the Company's stock splits in February 1997 and February 1999.
(4) Consists of matching contributions to the Savings and Investment Program
(SIP) and the Benefits Equalization Plan for the SIP as follows: Mr.
Heimbold ($52,942 and $7,200); Mr. Weg ($30,284 and $6,585); Mr. Mee
($21,285 and $7,200); Mr. Hayden ($20,865 and $6,585); Dr. Ringrose
($20,415 and $6,585) and Mr. McGoldrick ($19,290 and $6,585).
(5) Performance-based exercise price thresholds must be attained for portions
of the 1998 and 1999 awards to become exercisable. Award amounts reflect
the stock split in February 1999.
(6) Performance-based thresholds for the 1997 awards have been attained so
those awards are exercisable to the extent that time vesting criteria have
been met. Award amounts reflect the stock splits in February 1997 and
February 1999.
(7) Long-Term Performance Award granted in 1997 and earned over the three-year
performance period from 1997 through 1999. The payout was based on total
stockholder return ranking versus peer companies. This award was paid at
180% of target.
(8) Long-Term Performance Award granted in 1996 and earned over the three-year
performance period from 1996 through 1998. The payout was based on the
achievement of three-year compounded annual earnings per share, sales and
cash flow growth objectives along with a total stockholder return
multiplier. This award was paid at 112.9% of target.
(9) Long-Term Performance Award granted in 1995 and earned over the three-year
performance period from 1995 through 1997. The payout was based on the
achievement of three-year compounded annual earnings per share, sales and
cash flow growth objectives along with a total stockholder return
multiplier. This award was paid at 112.19% of target.
(10) Mr. Weg was President, Worldwide Medicines Group until December 1, 1998
when he joined the Office of the Chairman. He was elected Vice Chairman
effective May 4, 1999.
(11) Effective January 20, 2000, Mr. Mee became Executive Vice President & Chief
Financial Officer.
(12) Mr. Hayden was President, Intercontinental Region until December 1, 1998
when be became Senior Vice President and President, Worldwide Medicines
Group. Effective January 20, 2000, he became Executive Vice President,
Strategy.
(13) Effective January 20, 2000, Dr. Ringrose became Chief Scientific Officer.
(14) These awards were granted before Dr. Ringrose joined the Company.
(15) Mr. McGoldrick was Senior Vice President, Law and Strategic Planning and
General Counsel until December 1, 1998 when he became Senior Vice
President, General Counsel and President, Medical Devices Group. Effective
January 20, 2000, he became Executive Vice President, General Counsel and
President, Medical Devices Group.
--
=======================================================
James Love, Director | http://www.cptech.org
Consumer Project on Technology | mailto:love@cptech.org
P.O. Box 19367 | voice: 1.202.387.8030
Washington, DC 20036 | fax: 1.202.234.5176
=======================================================